Pharmacokinetics of trofosfamide and its dechloroethylated metabolites

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 1, 1997, Pages 45-50

  Hempel, Georg ^a   Krümpelmann, Sebastian ^a   May Manke, Antje ^b   Hohenlöchter, Barbara ^a   Blaschke, Gottfried ^b   Jürgens, Heribert ^a   Boos, Joachim ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Cyclophosphamide; Ifosfamide; Oral chemotherapy; Trofosfamide

Indexed keywords

2 DECHLOROETHYLIFOSFAMIDE; 3 DECHLOROETHYLIFOSFAMIDE; CYCLOPHOSPHAMIDE; DRUG METABOLITE; ETOPOSIDE; IFOSFAMIDE; TROFOSFAMIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIQUID LIQUID EXTRACTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030932345     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050623     Document Type: Article

References (22)

1. Blaschke G, Koch U (1986) Gaschromatographische Bestimmung und Enantiomerentrennung von Ifosfamid sowie der Metaboliten 2- und 3-Deschlorethylifosfamide. Arch Pharm 319:1052
2. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR (1993) Pharmacokinetics and metabolism of Ifosfamide administrated as a continuous infusion in children. Cancer Res 53:3758
3. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR (1995) Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer 31A:785
4. Boos J, Welslau U, Ritter J, Blaschke G, Schellong G (1991) Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother Pharmacol 28:455-480
5. Boos J, Küpker F, Blaschke G, Jürgens H (1993) Trofosfamide metabolism in different species ifosfamide is the predominant metabolite. Cancer Chemother Pharmacol 33:71
6. Brade WP, Herdrich K, Kachel-Fischer U, Araujo CE (1991) Dosing and side effects of ifosfamide plus mesna. J Cancer Res Clin Oncol 117 [Suppl VI]: 164
7. Brock N (1973) Pharmakologische Untersuchungen mit Trofosfamide, einem neuen Oxazaphosphorinoxid. Med Monatsschr 27:300
8. Burk CD, Restaino I, Kaplan BS, Meadows AT (1990) Ifosfamide-induced renal tubular dysfunction and rickets in children with Willms' tumor. J Pediatr 117:331
9. Cerny T, Margison JM, Thatcher M, Wilkinson PM (1986) Bioavailability of ifosfamide in patients with bronchial carcinoma. Cancer Chemother Pharmacol 19:261
10. Curtin JP, Koonings PP, Guiterrez M, Schlaerth JB, Morrow CP (1991) Ifosfamide-induced neuro-toxicity. Gynecol Oncol 42:193
11. Dechant KL, Brodgen RN, Pilkington T, Faulds D (1991) Ifosfamide/mesna: a review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42:428
12. Drings P, Allner R, Brock N, et al (1970) Erfahrungen mit neuartigen N-Lost-Phosphamidestem. Dsch Med Wochenschr 10:491 497
13. Falkson G, Falkson HC (1987) Trofosfamide in the treatment of patients with cancer. S Afr Med J 53:886
14. Goren MP, Wright RK, Pratt CB, Pell FE (1986) Dechloroethylation of ifosfamide and neurotoxicity. Lancet II: 1219
15. Henning B, Rädler S, Blaschke G, Boos J (1992) Festphasen-Probenvorbereitung von ifosfamide und seinen Deschlorethyl-metaboliten in biologischem Material. Pharmazie 4:783
16. Kaijser GP, Korst A, Beijnen JH, Bult A, Underberg WJM (1993) The analysis of ifosfamide and its metabolites (review). Anticancer Res 13:1311
17. Krümpelmann S, Hohenlöchter B, Tillmann B, Wolff J, Kuhn N, Langer D, Herrmann J, Steen A, Jürgens H, Boos J (1995) Intensive and prolonged treatment with oral trofosfamide and etoposide on an outpatient basis. Med Pediatr Oncol 25:231
18. Kurowski V, Wagner T (1993) Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2-and 3-dechloroethylifosfamide in patiens on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33:36
19. Skubitz KM, Hamdan H, Thomson RC (1993) Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcoma. Cancer 15: 10
20. Wagner T (1994) Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet 26:436
21. Wagner T, Fenneberg K (1984) Pharmacokinetics and bioavailability of cyclophosphamide from oral formulations. Arzneimittelforschung 34:313
22. Wist E, Risberg T (1991) Trofosfamide in non-Hodgkin's lymphoma a phase II study. Acta Oncol 30:819